CG Oncology, Inc.
CG Oncology is a clinical-stage biopharmaceutical company based in Dallas, Texas. It develops cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for patients with bladder cancer. The treatment is designed to eliminate cancer cells directly through selective replication and indirectly by activating an anti-tumor immune response. CG Oncology evaluates cretostimogene alone in the Phase 3 BOND-003 trial for high-risk bladder cancer and in the Phase 3 PIVOT-006 trial for intermediate-risk disease. Its Phase 2 CORE-008 trial assesses the treatment alone and in combination with gemcitabine in high-risk patients. The company has also studied cretostimogene with pembrolizumab. CG Oncology uses third parties for product manufacturing.
Guggenheim kept CG Oncology at Buy but reduced its price target to $89 from $90, a 1.1% decrease. The new target suggests a 17.1% upside from the Nov 6 close of $75.99.
CG Oncology (CGON) stock rose 19.7% after Q3 2026 results showed a smaller-than-expected loss of $0.64 per share and revenue of $1.60M, both beating estimates. The company announced upcoming clinical trial data and a BLA submission, with a cash position of $984.5M. Analysts have a 'Moderate Buy' rating and $87.50 average price target.
CG Oncology, Inc. (CGON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates • PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk and high-grade Ta NMIBC anticipated November 2026 • BOND-003 Coho
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning CGON (CG Oncology, Inc.). Coverage has skewed bearish: 1 bullish, 2 neutral, and 2 bearish.
Recent CGON coverage spans financial news, earnings and insider activity.
In the last 30 days, CGON insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($62K). The most active reporter was POST LEONARD E with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst price target reduction may pressure the stock.
Earnings beat and strong cash position lift sentiment; upcoming trial data may sustain upside.
The earnings miss and sizable loss may pressure the stock, but the strong cash position and upcoming data could support upside if trials succeed.
Small insider sale likely has minimal price impact given low volume and value.
Minor secondary market sale; unlikely to move price materially.
AlphAI scores every news story that mentions CGON with an AI model for sentiment and relevance, and aggregates insider trades from CG Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Guggenheim kept CG Oncology at Buy but reduced its price target to $89 from $90, a 1.1% decrease. The new target suggests a 17.1% upside from the Nov 6 close of $75.99.
CG Oncology (CGON) stock rose 19.7% after Q3 2026 results showed a smaller-than-expected loss of $0.64 per share and revenue of $1.60M, both beating estimates. The company announced upcoming clinical trial data and a BLA submission, with a cash position of $984.5M. Analysts have a 'Moderate Buy' rating and $87.50 average price target.
CG Oncology, Inc. (CGON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates • PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk and high-grade Ta NMIBC anticipated November 2026 • BOND-003 Coho
CG Oncology (CGON) officer Ambaw Bellete plans to sell 826 shares, worth $61,950, on September 11, 2026, following a stock option exercise. The sale will be executed through Morgan Stanley Smith Barney LLC. The filing also lists Bellete's prior sales, including 100,000 shares on August 19, 2026, for $7,954,105.
CG Oncology (CGON) shareholder Ambaw Bellete plans to sell 5,789 shares via option exercise, with Morgan Stanley facilitating. The sale is part of ongoing secondary market activity, not a new issuance, and is set to close by August 27, 2026, according to a Rule 144 filing.
CG Oncology, a $7B biotech firm, moved its HQ from Irvine to Dallas, citing business benefits. The company, listed on Nasdaq, focuses on bladder cancer treatments.
CG Oncology (CGON) officer Ambaw Bellete filed a Form 144 notice to sell 5,762 shares of common stock, following a stock option exercise. Bellete has sold significant shares in recent months, including 100,000 shares on August 19, 2026, for $7.95M. Morgan Stanley Smith Barney LLC is the broker.
CG Oncology (NASDAQ: CGON) reported Q2 2026 results for the quarter ended June 30, 2026, with net loss of $79.1 million, or $0.90 per share. Cash, cash equivalents and marketable securities were about $1.0 billion, funding operations through 2029. The company said PIVOT-006 topline data are expected soon, and a BLA for HR BCG-unresponsive NMIBC is expected in Q4 2026.
CG Oncology, Inc. (CGON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates • PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-term • BLA completion for HR BCG-u
Mulay James sold 24,165 shares of CG Oncology, Inc. (CGON) at $75.16 ($1.82M total) on 2026-07-10 under a Rule 10b5-1 trading plan.
